MX2016014414A - Vacuna de peptido que comprende un peptido ras mutante y un agente quimioterapeutico. - Google Patents

Vacuna de peptido que comprende un peptido ras mutante y un agente quimioterapeutico.

Info

Publication number
MX2016014414A
MX2016014414A MX2016014414A MX2016014414A MX2016014414A MX 2016014414 A MX2016014414 A MX 2016014414A MX 2016014414 A MX2016014414 A MX 2016014414A MX 2016014414 A MX2016014414 A MX 2016014414A MX 2016014414 A MX2016014414 A MX 2016014414A
Authority
MX
Mexico
Prior art keywords
peptide
chemotherapeutic agent
mutant ras
vaccine
cancer
Prior art date
Application number
MX2016014414A
Other languages
English (en)
Inventor
Amund Eriksen Jon
Gaudernack Gustav
Original Assignee
Targovax Asa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=50679896&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX2016014414(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Targovax Asa filed Critical Targovax Asa
Publication of MX2016014414A publication Critical patent/MX2016014414A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001154—Enzymes
    • A61K39/001164—GTPases, e.g. Ras or Rho
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/82—Translation products from oncogenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5158—Antigen-pulsed cells, e.g. T-cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55522—Cytokines; Lymphokines; Interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/58—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation
    • A61K2039/585—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation wherein the target is cancer

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Oncology (AREA)
  • Cell Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Virology (AREA)
  • Zoology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Biotechnology (AREA)
  • Hematology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

Se da a conocer al menos un péptido adecuado para provocar una respuesta inmune, para su uso en el tratamiento del cáncer. El, o cada, péptido corresponden a un fragmento de la proteína RAS, pero tiene de una a tres mutaciones puntuales de la misma. Al menos un péptido es para uso en el tratamiento del cáncer mediante la administración simultánea o secuencial con un agente quimioterapéutico antimetabolito.
MX2016014414A 2014-05-06 2015-05-05 Vacuna de peptido que comprende un peptido ras mutante y un agente quimioterapeutico. MX2016014414A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP14167265 2014-05-06
PCT/EP2015/059861 WO2015169804A1 (en) 2014-05-06 2015-05-05 Peptide vaccine comprising mutant ras peptide and chemotherapeutic agent

Publications (1)

Publication Number Publication Date
MX2016014414A true MX2016014414A (es) 2017-02-23

Family

ID=50679896

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2016014414A MX2016014414A (es) 2014-05-06 2015-05-05 Vacuna de peptido que comprende un peptido ras mutante y un agente quimioterapeutico.

Country Status (16)

Country Link
US (1) US9757439B2 (es)
EP (1) EP3140320B1 (es)
JP (2) JP2017514847A (es)
KR (1) KR20170002563A (es)
CN (1) CN106414493A (es)
AU (1) AU2015257774B2 (es)
BR (1) BR112016025764A2 (es)
CA (1) CA2947963A1 (es)
CL (1) CL2016002794A1 (es)
DK (1) DK3140320T3 (es)
ES (1) ES2716923T3 (es)
IL (1) IL248671B (es)
MX (1) MX2016014414A (es)
RU (1) RU2700929C2 (es)
SG (2) SG11201608712PA (es)
WO (1) WO2015169804A1 (es)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3369432A1 (en) 2013-12-09 2018-09-05 Targovax Asa A peptide mixture
AU2017347837A1 (en) 2016-10-26 2019-06-06 Modernatx, Inc. Messenger ribonucleic acids for enhancing immune responses and methods of use thereof
CA3051252A1 (en) 2017-02-01 2018-08-09 Modernatx, Inc. Immunomodulatory therapeutic mrna compositions encoding activating oncogene mutation peptides
CN110709094A (zh) * 2017-02-03 2020-01-17 威斯康星州医药大学股份有限公司 Kras肽疫苗组合物及其使用方法
WO2020002650A1 (en) 2018-06-29 2020-01-02 Targovax Asa A formulation
CN109550044B (zh) * 2018-10-19 2022-05-03 杭州纽安津生物科技有限公司 通用性多肽疫苗及其在制备治疗/预防胰腺癌药物中的应用
US20230000960A1 (en) * 2019-06-12 2023-01-05 Biontech Us Inc. Neoantigen compositions and uses thereof
CN113416241B (zh) * 2020-04-09 2022-04-08 北京臻知医学科技有限责任公司 一种用于诱导肿瘤特异性免疫响应的通用型抗原肽库及试剂盒
WO2022026620A1 (en) * 2020-07-29 2022-02-03 Sqz Biotechnologies Company Methods to stimulate immune responses to mutant ras using nucleated cells
KR20230058388A (ko) * 2020-07-29 2023-05-03 에스큐지 바이오테크놀로지스 컴퍼니 무핵 세포를 사용해 돌연변이체 ras에 대한 면역 반응을 자극하는 방법
AU2021389909A1 (en) * 2020-11-24 2023-06-22 Shanghai GenBase Biotechnology Co., Ltd. Ras mutant epitope peptide and t cell receptor recognizing ras mutant
WO2023220434A2 (en) * 2022-05-12 2023-11-16 The Johns Hopkins University Neoantigen vaccines for cancer prevention

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9103974D0 (en) * 1991-02-26 1991-04-10 Norsk Hydro As Therapeutically useful peptides or peptide fragments
GB2328689A (en) 1997-08-27 1999-03-03 Norsk Hydro As Peptides based on the p21 ras proto-oncogene protein for the treatment of cancer
NO309798B1 (no) * 1999-04-30 2001-04-02 Targovax As Peptidblanding, samt farmasoytisk sammensetning og kreftvaksine som innbefatter peptidblandingen
EP1581174B1 (en) 2002-12-16 2018-04-25 GlobeImmune, Inc. Yeast-based vaccines as immunotherapy
US20140199405A1 (en) 2013-01-11 2014-07-17 Abraxis Bioscience, Llc Method for treating cancer based on mutation status of k-ras
EP3369432A1 (en) 2013-12-09 2018-09-05 Targovax Asa A peptide mixture

Also Published As

Publication number Publication date
US9757439B2 (en) 2017-09-12
IL248671B (en) 2021-08-31
CN106414493A (zh) 2017-02-15
RU2016147527A (ru) 2018-06-08
KR20170002563A (ko) 2017-01-06
CA2947963A1 (en) 2015-11-12
DK3140320T3 (en) 2019-04-15
BR112016025764A2 (pt) 2018-01-16
IL248671A0 (en) 2017-01-31
EP3140320A1 (en) 2017-03-15
AU2015257774A1 (en) 2016-12-22
SG10201809701TA (en) 2018-12-28
JP2017514847A (ja) 2017-06-08
US20170065694A1 (en) 2017-03-09
SG11201608712PA (en) 2016-11-29
ES2716923T3 (es) 2019-06-18
RU2700929C2 (ru) 2019-09-24
JP2020100650A (ja) 2020-07-02
EP3140320B1 (en) 2018-12-26
RU2016147527A3 (es) 2019-01-21
WO2015169804A1 (en) 2015-11-12
CL2016002794A1 (es) 2017-06-09
JP7304629B2 (ja) 2023-07-07
AU2015257774B2 (en) 2018-12-20

Similar Documents

Publication Publication Date Title
MX2016014414A (es) Vacuna de peptido que comprende un peptido ras mutante y un agente quimioterapeutico.
MX2022004374A (es) Composiciones de agonista de tlr9 e inhibidores de punto de control para usarse en la respuesta inmune contra el cancer.
IL256687B (en) Isolated tau-binding antibody and its use in treatment and diagnosis
PH12017500022A1 (en) Carrier-antibody compositions and methods of making and using the same
MX2018014175A (es) Conjugados de anticuerpo-fármaco anti-cmet y métodos para su uso.
PH12016501618A1 (en) Anti-dll3 antibodies and drug conjugates for use in melanoma
CA2956871C (en) Compounds active towards bromodomains
MD20170032A2 (ro) Anticorpi anti-TIGIT
AU201612434S (en) Chair
MX2017005977A (es) Anticuerpos biespecificos y metodos de uso en oftalmologia.
MX370792B (es) Composiciones para usarse en el tratamiento de cáncer.
MY191539A (en) Streptococcal vaccine
MX2017005975A (es) Anticuerpos anti factor de crecimiento derivado de plaquetas b (pdgf-b) y metodos de uso.
MX2022013912A (es) Procedimientos novedosos para inducir una respuesta inmunitaria.
EP3348643A4 (en) MODIFIED INTERLEUKIN 12 AND USE THEREOF IN THE MANUFACTURE OF MEDICAMENTS FOR THE TREATMENT OF TUMORS
MX2019005309A (es) Anticuerpos anti-bag3 en combinacion con inhibidores del punto de control inmunitario para uso terapeutico.
HK1223630A1 (zh) 抗- 療法的實施與用量
PH12016501434A1 (en) Compositions for use in the treatment of allergic conditions
NZ728041A (en) Substances and methods for the use in prevention and/or treatment in huntington’s disease
PH12017501979A1 (en) Pharmaceutical compound
IL249860A0 (en) Pharmaceutical preparations, methods for their preparation and their use for the treatment of cancer
TWD174083S (zh) 電連接器之部分
EP3402370A4 (en) PREPARATIONS AND THERAPEUTIC ARTICLES
TWD174084S (zh) 電連接器之部分
TWD181173S (zh) 注射器噴嘴